Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Wegener’s Granulomatosis Treatment Market Outlook

The Wegener’s granulomatosis treatment market is estimated grow at a CAGR of 5.90% in the forecast period of 2024-2032. The market is expected to grow owing to the increasing prevalence of Wegener’s granulomatosis and improved governmental and private actions to increase understanding about the right diagnosis and treatment of such a rare ailment.

wegeners granulomatosis treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Wegener’s Granulomatosis Insights

GPA, or granulomatosis with polyangiitis (Wegener's), is a rare blood vessel disease. It is a potentially fatal autoimmune illness with an unclear cause. Since the inflammation in the blood vessel prevents optimal blood flow, the cells do not receive the oxygen they require. This results in tissue damage known as granulomatous inflammation. A granuloma is a form of cellular inflammation that is typically seen in biopsies of damaged organs.  The traditional clinical triad includes necrotizing granulomatous inflammation of the upper and/or lower respiratory tract, necrotizing glomerulonephritis, and an autoimmune necrotizing systemic vasculitis that primarily affects tiny arteries.

This rare condition is believed to impact 3 people out of every 100,000. It has an equal impact on males and women. GPA can happen at any age, although it is most common between the ages of 40 and 65. It is uncommon in children.

There is no single exam for determining GPA. Many factors contribute to GPA diagnosis, including symptoms, physical examination, blood testing, and imaging procedures like X-rays, CT scans, or MRI.


Active GPA produces inflammation in the blood vessels and organs. Chronic inflammation in blood arteries or organs can lead to organ failure. Without therapy, GPA can rapidly develop, potentially leading to life-threatening kidney or lung failure. 

Those with active severe disease are frequently given a glucocorticoid (steroid) medicine, such as Prednisone in combination with Cyclophosphamide (Cytoxan), a chemotherapy treatment. Prednisone is given at a high dose and progressively tapered off over a period of weeks to months. Cyclophosphamide is administered orally or by injection for three to six months. Those who improve are subsequently shifted to another medicine for 2 or more years, such as Methotrexate (Rheumatrex, Trexall) or Azathioprine (Imuran, Azasan). Prednisone and Methotrexate may be used to treat those with less active illness.

According to the Wegener’s granulomatosis treatment market research report, the market can be categorised into the following segments: 

wegeners granulomatosis treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Diagnosis

  • Lab Test
    • Blood Test
    • Urine Test
  • Imaging Tests
    • Chest X-rays
    • CT Scan
    • MRI
  • Biopsy

Market Breakup by Drug

  • Medication
    • Steroids
    • Immunosuppressant
    • Others
  • Plasma Exchange

Wegener’s Granulomatosis Treatment Market Breakup by Route of Administration

  • Oral
  • Intravenous
  • Others

Market Breakup by Therapeutic Channel

  • Public
  • Private

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

wegeners granulomatosis treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Wegener’s Granulomatosis Epidemiology

The global prevalence is predicted to be between 1/6,400 and 42,000, with an annual incidence of 1/84,000 to 475,000. There is geographic and/or ethnic variation, with colder places and Caucasians having a higher occurrence. Childhood-onset disease has a female predominance, whereas adult-onset disease has a little male predominance.

Wegener’s Granulomatosis Treatment Market Drivers

The North American region is likely to lead the market throughout the projection period due to the higher incidence rate of Wegener’s granulomatosis. 3 per 100,000 people are affected by Wegener’s granulomatosis.    

Due to high prevalence rates, improved healthcare infrastructure and amenities, increased government activities, rising disposable income in this region, expansion of the healthcare system, and increasing approval rates for additional novel medications, the Asia Pacific region is expected to grow at the fastest rate. The market expansion is being driven by the region’s rapidly expanding healthcare infrastructure, particularly in China and India, and the region’s increased awareness of rare disease treatment.

Clinical studies and increased R&D spending have allowed for the introduction of novel medicine molecules to the market. The companies are developing potential drug options to improve the treatment of GPA. 

Additionally, enhanced governmental and private actions to increase information regarding correct diagnosis and treatment of such a rare ailment, technology improvements, increased public health awareness, and favourable reimbursement rules will boost the market expansion.

Therapeutic Trends and Innovation

The increased use of monoclonal antibodies and recent advances in systemic treatment of Wegener's granulomatosis, including the introduction of investigational immunosuppressive drugs, such as Etanercept, Leflunomide, and Deoxyspergualin, are expected to shift the conventional treatment paradigm.

ChemoCentryx, Inc. gained USFDA approval for TAVNEOS (avacopan) in October 2021. It is used to treat adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), specifical Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). It is an orally administered selective complement 5a receptor inhibitor used in conjunction with conventional therapy.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the Wegener’s granulomatosis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

  • Sonoma Pharmaceuticals, Inc.
  • GSK plc
  • Halozyme Therapeutics, Inc
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Aprogen, Inc.
  • Amgen, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Pfizer Inc.
  • Novartis AG

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Diagnosis Method
  • Drug Classification
  • Route of Administration
  • Therapeutic Channel
  • Region
Breakup by Diagnosis Method
  • Lab Test
  • Imaging tests
  • Biopsy
Breakup by Drug Classification
  • Medication
  • Plasma Exchange
Breakup by Route of Administration
  • Oral
  • Intravenous
  • Others
Breakup by Therapeutic Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
  • Market Events, Initiatives & Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Sonoma Pharmaceuticals, Inc.
  • GSK plc
  • Halozyme Therapeutics, Inc
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Aprogen, Inc.
  • Amgen, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Pfizer Inc.
  • Novartis AG

Wegener’s Granulomatosis Treatment Market Report Snapshots

Wegener’s Granulomatosis Treatment Market Size

Wegener’s Granulomatosis Treatment Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market is likely to grow at a CAGR of 5.90% during the forecast period of 2024-2032.

The market is expected to witness significant growth owing to the increasing prevalence of Wegener’s granulomatosis, improved actions to increase understanding about the right diagnosis and treatment of such a rare ailment, technology improvements, an increase in public health awareness, and favourable reimbursement regulations.

North America is the dominating region in the market owing to the rising demand for the market.

Sonoma Pharmaceuticals, Inc., GSK plc, Halozyme Therapeutics, Inc, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Aprogen, Inc., Amgen, Inc., Epirus Biopharmaceuticals, Inc., Pfizer Inc., and Novartis AG, among others, are the leading companies in the market.

Yes, Wegener’s is an autoimmune disease. There is currently no cure but early diagnosis and adequate treatment can put the disease into relapse, allowing many patients to live full, productive lives. GPA, if left untreated, can cause possibly fatal organ damage or failure.

A tissue biopsy is required to confirm the diagnosis of Wegener granulomatosis. Biopsies of the upper respiratory tract reveal acute and chronic inflammation with granulomatous alterations. Kidney biopsies generally reveal segmental necrotizing pauci-immune glomerulonephritis, which is frequently angiocentric.

Pulmonologist (lung specialist); an otolaryngologist (ear, nose, and throat specialist); a nephrologist (kidney specialist); or a bone and joint specialist (rheumatologist) should be consulted to manage Wegener’s granulomatosis.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124